HC Wainwright Analysts Lower Earnings Estimates for TRDA

Key Points

• HC Wainwright cut Entrada Therapeutics’ Q3 2026 EPS estimate to a loss of $1.18 from $1.17 and maintained a Neutral rating. Analysts expect continued losses, including a projected full-year 2026 loss of $4.19 per share.
• Entrada’s latest quarterly results missed expectations, with a $1.01-per-share loss versus the anticipated $0.97 loss and revenue of $0.90 million compared with the $2.32 million consensus.
• Analyst sentiment remains mixed, with a consensus Hold rating and $17.50 price target, while institutional investors own 86.39% of the stock. Shares recently traded near $7.04, well below the consensus target.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Equities researchers at HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of Entrada Therapeutics in a research note issued on Monday, August 10th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($1.18) per share for the quarter, down from their prior forecast of ($1.17). HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for Entrada Therapeutics' current full-year earnings is ($4.07) per share. HC Wainwright also issued estimates for Entrada Therapeutics' Q4 2026 earnings at ($1.04) EPS, FY2026 earnings at ($4.19) EPS and FY2027 earnings at ($3.13) EPS.

A number of other equities research analysts also recently weighed in on TRDA. Weiss Ratings downgraded shares of Entrada Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a research report on Thursday, June 11th. Guggenheim dropped their price objective on Entrada Therapeutics from $20.00 to $17.00 and set a "buy" rating for the company in a report on Monday, June 8th. Finally, Roth Capital set a $10.00 target price on Entrada Therapeutics in a report on Friday, May 8th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Entrada Therapeutics currently has a consensus rating of "Hold" and a consensus price target of $17.50.

Entrada Therapeutics Stock Up 1.3%

Shares of Entrada Therapeutics stock opened at $7.04 on Wednesday. The stock has a market capitalization of $274.14 million, a price-to-earnings ratio of -1.78 and a beta of -0.26. Entrada Therapeutics has a twelve month low of $5.02 and a twelve month high of $16.45. The company has a 50-day simple moving average of $6.87 and a two-hundred day simple moving average of $9.65.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%.The firm had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.32 million.

Hedge Funds Weigh In On Entrada Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in shares of Entrada Therapeutics during the second quarter worth $19,013,000. Millennium Management LLC boosted its holdings in shares of Entrada Therapeutics by 391.2% during the 3rd quarter. Millennium Management LLC now owns 836,609 shares of the company's stock valued at $4,852,000 after acquiring an additional 666,287 shares in the last quarter. Citadel Advisors LLC grew its position in Entrada Therapeutics by 234.5% during the 3rd quarter. Citadel Advisors LLC now owns 335,741 shares of the company's stock worth $1,947,000 after acquiring an additional 235,384 shares during the last quarter. Baker BROS. Advisors LP grew its position in Entrada Therapeutics by 4.3% during the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company's stock worth $52,148,000 after acquiring an additional 206,911 shares during the last quarter. Finally, Qube Research & Technologies Ltd increased its holdings in Entrada Therapeutics by 115.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 287,873 shares of the company's stock worth $1,670,000 after purchasing an additional 154,143 shares in the last quarter. Institutional investors own 86.39% of the company's stock.

Insiders Place Their Bets

In related news, major shareholder Ventures V. L.P. 5Am sold 52,317 shares of the firm's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $6.85, for a total value of $358,371.45. Following the sale, the insider directly owned 2,783,781 shares of the company's stock, valued at $19,068,899.85. This trade represents a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Bernhardt G. Zeiher bought 5,000 shares of the stock in a transaction on Wednesday, May 20th. The shares were acquired at an average cost of $5.86 per share, with a total value of $29,300.00. Following the purchase, the director owned 5,000 shares of the company's stock, valued at approximately $29,300. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold 451,014 shares of company stock worth $3,124,822 over the last three months. Insiders own 9.49% of the company's stock.

Key Entrada Therapeutics News

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: Institutional ownership remains high at approximately 86.4%. BlackRock opened a position worth about $19.0 million, while Millennium Management, Citadel Advisors and Qube Research increased their holdings. These purchases may provide some underlying demand for TRDA shares.
• Positive Sentiment: Analyst coverage remains mixed but includes three Buy ratings. The average price target is reported at $17.50, well above recent trading levels, although HC Wainwright downgraded the stock to Neutral and Guggenheim lowered its target to $17.00. Entrada Therapeutics analyst and stock information
• Neutral Sentiment: Reported short interest was zero shares, with a zero-day days-to-cover ratio. Because the data also shows an “NaN” change from the prior period, it offers little reliable insight into current short-selling pressure.
• Negative Sentiment: Major shareholder Ventures V. L.P. 5Am sold a combined 62,811 shares on August 6 and 7 for approximately $431,829, reducing its position by about 2.2%. The shareholder still owns more than 2.7 million shares, so the sales represent a modest reduction rather than a full exit. SEC filing on Ventures V. L.P. 5Am share sales
• Negative Sentiment: Director Kush Parmar sold 155,255 shares across three transactions from August 6 through August 10 for roughly $1.08 million, cutting his holdings by approximately 5.5%. Repeated insider selling can weigh on sentiment, even though he continues to hold a substantial stake. SEC filing on Kush Parmar share sales
• Negative Sentiment: Entrada’s latest quarterly results missed expectations: adjusted loss per share was $1.01 versus an expected $0.97 loss, while revenue of $0.90 million fell short of the $2.32 million consensus. The clinical-stage biotechnology company is expected to remain unprofitable, with analysts forecasting a full-year loss of approximately $4.07 per share.

Entrada Therapeutics Company Profile

Entrada Therapeutics NASDAQ: TRDA is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source